Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Queensland Health
McKesson
Chinese Patent Office
Fish and Richardson
Cantor Fitzgerald
UBS
Federal Trade Commission
Deloitte
Accenture

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,085,553

« Back to Dashboard

Which drugs does patent 9,085,553 protect, and when does it expire?

Patent 9,085,553 protects XIIDRA and is included in one NDA.

This patent has thirteen patent family members in eleven countries.
Summary for Patent: 9,085,553
Title:LFA-1 inhibitor and methods of preparation and polymorph thereof
Abstract: Methods of preparation and purification of a compound of Formula I, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed. ##STR00001##
Inventor(s): Zeller; James Robert (Scottsdale, AZ), Venkatraman; Sripathy (Slingerlands, NY), Brot; Elisabeth C. A. (Albany, NY), Iyer; Subashree (Guilderland, NY), Hall; Michael (Albany, NY)
Assignee: SARCODE BIOSCIENCE, INC. (Brisbane, CA)
Application Number:13/950,807
Patent Claim Types:
see list of patent claims
Use; Composition; Process;

Drugs Protected by US Patent 9,085,553

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Shire Dev Llc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,085,553

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,708,303 LFA-1 inhibitor and methods of preparation and polymorph thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,085,553

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Hong Kong 1210145 ➤ Subscribe
Hong Kong 1210782 ➤ Subscribe
India 847DEN2015 ➤ Subscribe
Japan 2015523398 ➤ Subscribe
South Korea 20150067129 ➤ Subscribe
European Patent Office 2877465 ➤ Subscribe
Mexico 2015001098 ➤ Subscribe
China 104797574 ➤ Subscribe
Canada 2879982 ➤ Subscribe
Australia 2017265071 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Cipla
Colorcon
Chinese Patent Office
Express Scripts
US Army
Federal Trade Commission
QuintilesIMS
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot